Navigation Links
Diabetes Drug Slows Clogging of Arteries
Date:3/31/2008

Actos better at fighting plaque build-up than older medication, study finds

MONDAY, March 31 (HealthDay News) -- The diabetes drug Actos is better than another diabetes drug, Amaryl, at slowing clogging of the arteries in patients with both type 2 diabetes and cardiovascular disease.

The Cleveland Clinic researchers behind the new findings say this is the first time that a diabetes medication has been shown to slow atherosclerosis, giving doctors new insight into which drugs may be most effective and safest for this group of patients.

"The biggest news here is that pioglitazone [Actos] appears safe, does not increase cardiovascular risk, and may even reduce it," said Dr. Robert Scott III, an assistant professor of internal medicine at the Texas A&M Health Science Center College of Medicine and senior staff cardiologist with Scott&White in Temple, Texas. "It looks safe to use in people with coronary artery disease, and it is well-tolerated. We may need another trial to see how it helps, but at least it doesn't hurt, and that was our biggest concern."

The findings are published in the April 2 issue of the Journal of the American Medical Association and were released Monday to coincide with a presentation at the American College of Cardiology annual meeting, in Chicago. The research was funded by Takeda Pharmaceuticals North America Inc., which makes Actos.

Individuals with type 2 diabetes are particularly susceptible to atherosclerosis, as evidenced by the fact that 75 percent of this group eventually die of cardiovascular disease.

Amaryl (glimepiride) belongs to a class of drugs known as sulfulonylureas, which have been prescribed for decades. Actos, along with its cousin Avandia, is a thiazolidinedione, a relatively new class of diabetes drugs.

Both Actos and Avandia appear to increase the risk of heart failure (the entire class now carries a black-box warning to that effect), but Avandia has been associated with an increased risk of heart attack, while Actos has been linked with a reduced risk of negative cardiovascular outcomes.

"Both are associated with heart failure, but there were increased deaths [with Avandia]," said Dr. Stanley Mirsky, an endocrinologist with Lenox Hill Hospital in New York City and co-author of the Diabetes Survival Guide.

For this study, 543 patients with both coronary disease and type 2 diabetes were randomized to receive either Amaryl or Actos for 18 months. Actos works by making the body more sensitive to insulin, while Amaryl works by spurring the body to produce more insulin. All participants were also taking medications for heart disease.

Progression of atherosclerosis was measured by intravascular ultrasonography in the 360 patients who actually completed the study.

One measure found a 0.73 increase in plaque in the Amaryl group versus a 0.16 decrease in the Actos group. A second measure found a 0.64 increase for Amaryl and a 0.06 decrease for Actos.

The study was not designed to measure actual clinical endpoints, meaning cardiovascular events or death.

The authors stated that the exact mechanisms for the decreases associated with Actos were unclear, although several biomarkers linked to atherosclerosis progression were impacted by the drug, including a 16 percent increase in HDL or "good" cholesterol, a 15 percent reduction in triglyceride levels, and a 45 percent drop in C-reactive protein (CRP) levels.

It's also not clear if the benefits associated with Actos extend to other medications in that class of drugs.

An accompanying editorial found the results "reassuring."

"You've got to take into consideration the benefit of preventing heart attacks may be greater than the few people who get heart failure," Mirsky said.

More information

Visit the American Heart Association for more on atherosclerosis.



SOURCES: Robert Scott III, M.D., Ph.D., assistant professor, internal medicine, Texas A&M Health Science Center College of Medicine, and senior staff cardiologist, Scott & White, Temple, Texas; Stanley Mirsky, M.D., endocrinologist, Lenox Hill Hospital, associate clinical professor, metabolic disease, Mount Sinai School of Medicine, New York City, and co-author, Diabetes Survival Guide; March 31, 2008, presentation, American College of Cardiology annual meeting, Chicago; April 2, 2008, Journal of the American Medical Association


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Lung Capacity Declines Faster With Diabetes
2. A ton of bitter melon produces sweet results for diabetes
3. Pharsight Signs New Diabetes Meta-Database Customer
4. AUDIO from Medialink and Solvay Pharmaceuticals: Men with Type 2 Diabetes at Increased Risk for Low Testosterone Should Talk to Their Doctors
5. AUDIO from Medialink and Pfizer: The 20th Annual American Diabetes Alert Day Reminds Us to Learn if We Are at Risk
6. A link between antidepressants and type 2 diabetes
7. NYU dental researchers find evidence of periodontal disease leading to gestational diabetes
8. Video: Could You Be At Risk? American Diabetes Association Sounds the Alert on March 25th - ADAs 20th Annual American Diabetes Alert(R) Day
9. More Vitamin D in Childhood Cuts Later Diabetes Risk
10. Diabetes Toll Continues to Grow
11. Columbia University Medical Center/NYPH receive $28 million donation toward curing diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Diabetes Drug Slows Clogging of Arteries
(Date:4/29/2016)... Tarzana, CA (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type ... is to blame for the majority of skin cancer deaths. More than 10,000 people are ... average age at diagnosis is 62, it is the one of the most commonly diagnosed ...
(Date:4/29/2016)... ... April 29, 2016 , ... For those who skip ... meal to miss. That was among the many new lifestyle diet tips offered by ... Sharon Kleyne Hour® Power of Water® radio show. Bonny and Lawrence noted that because ...
(Date:4/29/2016)... ... April 29, 2016 , ... CURE ... entirely on patients with cancer, today announced that Lynne Malestic, RN, of Eisenhower ... 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors nurses who have ...
(Date:4/29/2016)... ... April 29, 2016 , ... International Dehydrated Foods, Inc. ... May 3 and 4 at the Doubletree by Hilton Hotel in Oak Brook, Illinois. ... marketing and applications technologies for protein ingredients. , At the seminar, IDF™ will offer ...
(Date:4/29/2016)... Wilmington, DE (PRWEB) , ... April 29, 2016 ... ... annual SMG Finance, which will be held May 16th to 18th at the ... all of the SMG managed facilities to collaborate on best practices in public ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016 Dr. ... und Stephen Schmidt werden ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen für ... dass neue Führungskräfte zum Team Sicherheit und ... vielfältige Erfahrungen mitbringen.  Dies wird die Geschäftseinheit ...
(Date:4/28/2016)... -- Dr. Vivek Ahuja , ... Ste phen Schmidt Join ... cloud-based software solutions for life sciences, today announced key new leaders ... of insight to a growing business.  This will bolster the company,s ... Phillips joined ArisGlobal in the position of Vice President - ...
(Date:4/28/2016)... Florida , April 28, 2016 ... the development of innovative peptide and gene-based immunotherapeutics and vaccines ... it will be presenting at the 3rd Annual Growth ... - 5 th , 2016 at Caesars Palace in Las Vegas, ... 8.00 am on Wednesday, May 4 th by Dr. ...
Breaking Medicine Technology: